

Country support and GFATM related matters

No 2.04/1b

Annex I

Summary of GFATM approvals, rounds 1-4 Number of components and Amount of funding					
Round	Total number of approved components (all diseases)	Number of components	TB % of all approved components	Approved 2-year funding for TB (US\$)	TB % of all approved 2-year funding (all diseases)
1	55	12 TB	23 %	96,425,410	17 %
		4 TB/HIV	8 %	54,762,738	10 %
2	98	25 TB	26 %	115,020,918	18 %
		1 TB/HIV	1 %	8,414,000	1 %
3	74	18 TB	24 %	67,850,151	8 %
		2 TB/HIV	3 %	26,618,380	3 %
4	71	21 TB	30%	153,035,878	15 %

GFATM Board approval success (rounds 1-4)							
Round	Component	approved (cat 1)	approved (cat 2)	rejected (cat 3)	rejected (cat 4)	% approved of those submitted	Total number reviewed by TRP
1	HIV	16	10	61	0	30%	87
	TB	10	2	18	0	40%	30
	TB/HIV	4	0	7	0	36%	11
	Malaria	10	2	60	0	17%	72
2	HIV	6	37	42	8	46%	93
	TB	4	21	30	2	44%	57
	TB/HIV	0	1	11	4	6%	16
	Malaria	1	27	31	5	44%	64
3	HIV	1	32	34	7	45%	74
	TB	3	17	25	1	43%	46
	TB/HIV	0	2	5	2	22%	9
	Malaria	1	19	23	6	41%	49
4	HIV	0	27	42	3	38%	72
	TB	1	18	26	4	40%	48
	TB/HIV	0	0	0	1	0%	1
	Malaria	1	22	21	3	49%	47

## **Annex II**

Countries intending to apply in R5:

### **AFRO:**

Botswana, Cap Verde, Comoros, Congo, DR Congo, Eritrea, Gabon, Gambia, Ghana, Guinea, Equitorial Guinea, Mozambique, Niger, Nigeria, Sao Tome and Principe, South Africa, Senegal, Tanzania, Zimbabwe

### **AMRO:**

Belize, Brazil, Guatemala, Suriname, Mexico

**EURO:** Albania, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Bugaria, Kazakhstan, Macedonia, Turkey, Turkmenistan, Ukraine

**SEARO:** India, Indonesia, Bangladesh, Myanmar.

**WPRO:** Cambodia, Philippines, Viet Nam, Papua New Guinea, Pacific Islands